KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Common Equity: 2018-2025

Historic Common Equity for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $467.0 million.

  • Castle Biosciences' Common Equity rose 5.89% to $467.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $467.0 million, marking a year-over-year increase of 5.89%. This contributed to the annual value of $455.8 million for FY2024, which is 16.50% up from last year.
  • Per Castle Biosciences' latest filing, its Common Equity stood at $467.0 million for Q3 2025, which was up 2.56% from $455.4 million recorded in Q2 2025.
  • Castle Biosciences' Common Equity's 5-year high stood at $467.0 million during Q3 2025, with a 5-year trough of $378.8 million in Q2 2023.
  • For the 3-year period, Castle Biosciences' Common Equity averaged around $420.6 million, with its median value being $423.9 million (2024).
  • In the last 5 years, Castle Biosciences' Common Equity surged by 376.02% in 2021 and then fell by 10.17% in 2023.
  • Castle Biosciences' Common Equity (Quarterly) stood at $411.7 million in 2021, then decreased by 3.06% to $399.1 million in 2022, then fell by 1.97% to $391.3 million in 2023, then rose by 16.50% to $455.8 million in 2024, then climbed by 5.89% to $467.0 million in 2025.
  • Its last three reported values are $467.0 million in Q3 2025, $455.4 million for Q2 2025, and $440.3 million during Q1 2025.